In this edition, blue-collar workers more likely to miss work or quit due to psoriatic arthritis, infliximab biosimilar increase after release of a third option and more.

Read the full coverage here:

Blue-collar workers more likely to miss work, quit due to psoriatic arthritis

Infliximab biosimilar uptake rapidly increased only after release of a third option

National Psoriasis Foundation to honor leaders at 2025 Commit to Cure Gala

Safety checklist compiles clinically important DMARD warnings in one place

Guselkumab demonstrates long-term efficacy, safety in psoriasis

References:

Colla N, et al. Clin Rheumatol. 2024;doi:10.1007/s10067-024-07077-1.

Gargiulo L, et al. J Drugs Dermatol. 2024;doi:10.36849/JDD.7486R1.

Press Release

Roberts ET, et al. Arthritis Rheumatol. 2024;doi:10.1002/art.42963.

Skaarup L, et al. Drug Saf. 2024;doi:10.1007/s40264-024-01461-1.

In this edition, FDA approves first subcutaneous anti-PD-L1 cancer immunotherapy, ivonescimab ‘may be a new standard’ and more.

Read the full coverage here:

FDA approves first subcutaneous anti-PD-L1 cancer immunotherapy

Ivonescimab extends PFS vs. pembrolizumab in advanced NSCLC, may be ‘a new standard’

Perioperative nivolumab improves outcomes in resectable NSCLC

Despite progress, barriers to lung cancer biomarker testing persist

Atezolizumab regimen ‘merits further study’ for unresectable NSCLC

References:

Forde PM, et al. Abstract 3589. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego.

Press Release

Ross HJ, et al. JAMA Oncol. 2024;doi:10.1001/jamaoncol.2024.1897.

Smeltzer M, et al. Abstract 3000. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego.

Zhou C, et al. Abstract 2700. Presented at: IASLC World Conference on Lung Cancer; Sept. 7-10, 2024; San Diego.

In this edition, screening program identifies airways disease in previously undiagnosed COPD, positive results show benefits of subcutaneous bispecifics and more.

Read the full coverage here:

Lung cancer screening program identifies airways disease in previously undiagnosed COPD

Positive results in lung cancer show benefits of subcutaneous bispecifics

Adagrasib delays progression of pretreated KRAS-mutant lung cancer

Durvalumab extends survival in limited-stage small-cell lung cancer

Osimertinib delays progression ‘way more’ than hoped in EGFR-mutant lung cancer

References:

Bernstein E, et al. JCO Precis Oncol. 2024;doi:10.1200/po.23.00447.

Leighl NB, et al. Abstract LBA8505. Presented at: ASCO Annual Meeting; May 30–June 3, 2024; Chicago.

Ramalingam SS, et al. Abstract LBA4. Presented at: ASCO Annual Meeting; May 31-June 4, 2024: Chicago.

Seigo MA, et al. Pulmonary comorbidities, respiratory symptoms, and spirometry in a real-world, urban lung cancer screening program. Presented at: American Thoracic Society International Conference; May 17-22, 2024; San Diego.

Spigel DR, et al. Abstract LBA3. Presented at: ASCO Annual Meeting; May 31-June 4, 2024: Chicago.

In this edition, Incidental respiratory findings on low-dose CT lung cancer screening common; lack of guideline-concordant treatment for early-stage non-small cell lung cancer common; women at greater risk for more severe adverse events from cancer treatments, and more.

Read the full coverage here:

Incidental respiratory findings on low-dose CT lung cancer screening common

Lack of guideline-concordant treatment for early-stage non-small cell lung cancer common

Women at greater risk for more severe adverse events from cancer treatments

Visual, quantitative CT emphysema assessments linked to higher odds of lung cancer

Acetaminophen may reduce immunotherapy efficacy in patients with cancer

References:

Bessede A, et al. Abstract LBA12000. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.

Kehl KL, et al. JAMA Oncol. 2022;doi: 10.1001/jamaoncol.2022.0039.

Pinsky PF, et al. Chest. 2022;doi:10.1016/j.chest.2021.11.015.

Unger JM, et al. J Clin Oncol. 2022;doi:10.1200/JCO.21.02377.

Yang X, et al. Radiol. 2022;doi:10.1148/212904.

In this week’s edition, women are less likely than men to return to work after large vessel occlusion stroke; cognitive impairment, headaches and CVD are more common in former college football players; veterans, providers support the addition of integrative medicine for chronic headaches; and more.

Read the full coverage here:

Women less likely than men to return to work after large vessel occlusion stroke

Cognitive impairment, headaches, CVD more common in former college football players

Veterans, providers support addition of integrative medicine for chronic headaches

New blood biomarker may lead to early diagnosis of frontotemporal dementia

Phase 2 trial shows promising results for oral Parkinson’s treatment

References:

Hahn M, et al. Stroke. 2022;doi:10.1161/STROKEAHA.121.037386.

Phelps A, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2022.8775.

Press Release

Press Release

Press Release

In this edition, late-stage colorectal, breast cancer diagnoses increase after start of COVID-19 pandemic; chemicals found in hair products increase viability of breast cancer cells in Black women; continued CDK 4/6 inhibition after breast cancer progression may benefit some patients; and more.

Read the full coverage here:

Late-stage colorectal, breast cancer diagnoses increase after start of COVID-19 pandemic

Chemicals found in hair products increase viability of breast cancer cells in Black women

Continued CDK 4/6 inhibition after breast cancer progression may benefit some patients

Some older women with luminal A breast cancer can safely forgo radiotherapy, study shows

Sacituzumab govitecan significantly extends PFS in advanced breast cancer subset

References:

Zhou JZ, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2021.48581.

Trevino L, et al. RF22 | PMON05. Presented at: ENDO Annual Meeting; June 11-14, 2022; Atlanta (hybrid meeting).

Kalinsky K, et al. Abstract LBA1004. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.

Source: Whelan TJ, et al. Abstract LBA501. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.

Rugo HS, et al. Abstract LBA1001. Presented at: ASCO Annual Meeting; June 3-7, 2022; Chicago.

In this week’s edition, CAR-T ‘robustly effective’ in younger patients with deadly form of brain cancer; SARS-CoV-2 linked to range of neurological diseases; Increased mortality risk for men with type 1 diabetes, regardless of cognitive ability; and more.

Read the full coverage here:

Steerable microcatheter nets FDA 510(k) clearance for neurologic, peripheral, coronary use

CAR-T ‘robustly effective’ in younger patients with deadly form of brain cancer

SARS-CoV-2 linked to range of neurological diseases

Risk for major adverse CV events elevated with type 2 diabetes, cognitive impairment

Increased mortality risk for men with type 1 diabetes, regardless of cognitive ability

References:

Press Release

Majzner RG, et al. Abstract CT001. Presented at: American Association for Cancer Research Annual Meeting; April 8-13, 2022; New Orleans.

Klein RS, et al. Neurobiology of COVID-19. Presented at: American Academy of Neurology annual meeting; April 2-7, 2022; Seattle.

Cukierman-Yaffe T, et al. J Clin Endocrinol Metab. 2022;doi:10.1210/clinem/dgac200

Dybjer E, et al. Diabet Med. 2022;doi:10.1111/dme.14806.

In this edition, AYA cancer survivors are at higher risk for death due to second primary cancers; a radiation technique reduces symptomatic esophagitis in patients with advanced lung cancer; a phase 3 trial of tiragolumab plus atezolizumab misses its co-primary endpoint; and more.

Read the full coverage here:

AYA cancer survivors at higher risk for death due to second primary cancers

Radiation technique reduces symptomatic esophagitis in patients with advanced lung cancer

Phase 3 trial of combination for advanced lung cancer misses co-primary endpoint

As proton beam therapy use for cancer increased, ‘so did the racial disparity in receipt’

Entrectinib induces durable, intracranial responses in NTRK fusion-positive solid tumors

References:

Sung H, et al. J Natl Cancer Inst. 2022;doi:10,1093/jnci/djac091.

Louie AV, et al. JAMA Oncol. 2022:doi:10.1001/jamaoncol.2021.7664.

Press Release

Nogueira LM, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2022.8970.

Demetri GD, et al. Clin Cancer Res. 2022;doi:10.1158/1078-0432.CCR-21-3597.

In this week’s edition, anxiety, depression worse among older men with vision impairment; emerging therapeutics may improve outcomes in pediatric patients with rare disorders; glioblastoma presents roadblock to successful immunotherapy; and more.

Read the full coverage here:

MRI findings key pathology markers of 4R-tauopathies

Emerging therapeutics may improve outcomes in pediatric patients with rare disorders

Together Senior Health launches platform to reduce memory loss in AD, dementia

Anxiety, depression worse among older men with vision impairment

Glioblastoma presents roadblock to successful immunotherapy

References:

Carlos AF, et al. Tau histopathological lesion type correlates of structural magnetic resonance imaging and diffusion tensor imaging biomarkers in 4-repeat tauopathies. Presented at: American Academy of Neurology annual meeting; April 2-7, 2022; Seattle.

Emrick L, et al. Emerging therapeutics for rare pediatric genetic disorders. Presented at: American Academy of Neurology annual meeting; April 2-7, 2022; Seattle.

Press Release

Gascoyne B, et al. Int Health. 2022;doi:10.1093/inthealth/ihab070

Kumthekar P. AAN year in review: neuro oncology. Presented at: American Academy of Neurology annual meeting; April 2-7, 2022; Seattle.

Read the full coverage here:

In this edition, diet, genetics and family history play role in AMD progression; omega-3 fatty acids may improve vision in dry AMD; long-term dopamine treatment may delay onset of diabetic retinopathy; and more.

Diet, genetics and family history play role in AMD progression

Omega-3 fatty acids may improve vision in dry AMD

Long-term dopamine treatment may delay onset of diabetic retinopathy

Anti-VEGF injections decrease aqueous VEGF levels in diabetic retinopathy

Novel ERG method aids in monitoring patients with posterior uveitis

References:

Williams BK. What to do for your patient with early dry AMD. Presented at: American Society of Cataract and Refractive Surgery meeting; April 22-26, 2022; Washington.

Prokopiou E, et al. A prospective, randomised, multicenter, double-blind, placebo-controlled study assessing the potential effects of omega-3 fatty acids supplementation on dry age-related macular degeneration and Stargardt disease. Presented at: Association for Research in Vision and Ophthalmology meeting; May 1-4, 2022; Denver.

Allen RS, et al. Dopamine treatment delays diabetic retinopathy onset in a retrospective study. Presented at: Association for Research in Vision and Ophthalmology meeting; May 1-4, 2022; Denver.

Mynampati BK, et al. Aqueous levels of VEGF decrease after serial intravitreal injections of anti-VEGF agents in patients with diabetic retinopathy. Presented at: Association for Research in Vision and Ophthalmology meeting; May 1-4, 2022; Denver.

Than NTT, et al. Flicker ERG findings in posterior uveitis. Presented at: Association for Research in Vision and Ophthalmology meeting; May 1-4, 2022; Denver.

In this week’s edition, childhood sexual and emotional abuse increases the risk for multiple sclerosis in women; fentanyl-related cardiac arrest is linked to worse neurological outcomes; Black patients with MS have a higher rate of disability compared with their white counterparts; and more.

Read the full coverage here:

Childhood sexual, emotional abuse increases multiple sclerosis risk in women

Fentanyl-related cardiac arrest linked to worse neurological injury, outcomes

Black MS patients have higher rate of disability than white counterparts

Brain stimulation software receives FDA approval for use in Parkinson’s disease

Seizure frequency, poor quality of life risk factors for depression in epilepsy patients

References:

Eid K, et al. J Neurol Neurosurg Psychiatry. 2022;doi:10.1136/jnnp-2021-328700.

Otero M, et al. Neurological injury and outcomes in fentanyl-related cardiac arrest. Presented at: American Academy of Neurology annual meeting; April 2-7, 2022; Seattle.

Dykes E, et al. Health disparities in African American patients with multiple sclerosis: a retrospective chart-review study. Presented at: American Academy of Neurology annual meeting; April 2-7, 2022; Seattle.

Press Release

Syed M, et al. Factors associated with depression in epilepsy patients: a population-based study in the Detroit metropolitan area. Presented at: American Academy of Neurology annual meeting; April 2-7, 2022; Seattle.

In this edition, early lung cancer detection improves survival rates; incidental respiratory findings on low-dose CT lung cancer screening common; certain patients may derive more benefit from immunotherapy for non-small cell lung cancer and more.

Read the full coverage here:

Early lung cancer detection improves survival rates

Incidental respiratory findings on low-dose CT lung cancer screening common

Certain patients may derive more benefit from immunotherapy for non-small cell lung cancer

Bispecific antibody shows durable benefit in advanced solid tumors

Enhertu receives priority review for HER2-mutated non-small cell lung cancer

References:

Healio Interview

Pinsky PF, et al. Chest. 2022;doi:10.1016/j.chest.2021.11.015.

Patel K, et al. JNCI Cancer Spectr. 2022;doi:10.1093/jncics/pkac015

Bispecific antibody shows durable benefit in advanced solid tumors

Press Release

In this week’s edition, risk for cognitive decline is associated with older COVID-19 survivors; a study validates an FDA-approved blood test for traumatic brain injury; and more.

Read the full coverage here:

Risk for cognitive decline associated with older COVID-19 survivors

Study validates FDA-approved blood test for traumatic brain injury

VA hospital telestroke networks improve treatment, lower ED transfer rate

Lower left atrial function associated with higher risk for dementia

Rates of neurological events higher with SARS-CoV-2 infection than with COVID-19 vaccine

References:

Liu YH, et al. JAMA Neurol. 2022;doi:10.1001/jamaneurol.2022.0461.

Papa L, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2022.1302.

Lyerly M, et al. Neurology. 2022;doi:10.1212/WNL.0000000000200143.

Wang W, et al. JAMA. 2022;doi:10.1001/jama.2022.2518

Li X, et al. BMJ. 2022;doi:10.1136/bmj-2021-068373.

In this edition, AI model helps predict anti-VEGF response in DME, Merck to acquire EyeBio and more.

Read the full coverage here:

VIDEO: AI model helps predict anti-VEGF response in diabetic macular edema

Merck to acquire EyeBio

VIDEO: IOP remains stable up to 48 weeks with aflibercept 8 mg for DME

Phase 2 study of potential DME oral therapy meets primary endpoints

FDA approves aflibercept biosimilars Yesafili, Opuviz

References:

Barakat MR. Intraocular pressure outcomes with intravitreal injection of aflibercept 8 mg and 2 mg in patients with diabetic macular edema through week 48 of the phase 2/3 PHOTON trial. Presented at: Association for Research in Vision and Ophthalmology meeting; May 5-9, 2024; Seattle.

Luvisi J. Using a convolutional neural network to predict response of diabetic macular edema to intravitreal anti-vascular endothelial growth factor. Presented at: Kiawah Eye; May 30-June 1, 2024; Kiawah Island, South Carolina.

Press Release

Press Release

Press Release

In this edition, European commission approves Beovu for DME, choroidal vascularity index linked with geographic atrophy progression, intravitreal gene therapy effective, safe in Leber hereditary optic neuropathy, and more.

Read the full coverage here:

Susvimo noninferior to monthly ranibizumab with similar efficacy

European Commission approves Beovu for DME

Intravitreal gene therapy effective, safe in Leber hereditary optic neuropathy

Teprotumumab may provide better outcomes than IV methylprednisolone in thyroid eye disease

Choroidal vascularity index linked with geographic atrophy progression

References:

Healio Interviews

Holekamp NM, et al. Ophthalmology. 2022;doi:10.1016/j.ophtha.2021.09.016.

Newman N, et al. The Phase III REFLECT Trial: Efficacy and safety of bilateral gene therapy for Leber hereditary optic neuropathy (LHON). Presented at: American Academy of Neurology Annual Meeting; April 2-7, 2022; Seattle.

Press Release

Sacconi R, et al. Retina. 2022;doi:10.1097/IAE.0000000000003305.

In this week’s edition, the FDA approval of an oral anticonvulsant; plus news you may have missed from the AAN and ACTRIMS meetings.

Read the full coverage here:

FDA approves oral anticonvulsant

New drug improved tic severity in children with Tourette syndrome

Vitamin D levels not associated with adverse outcomes in European MS patients

Zolpidem may be effective for prolonged disorders of consciousness

Amygdala overgrowth begins in first year of life in infants with ASD

References:

Press Release

Gilbert DL, et al. ES1.002: Ecopipam in children and adolescents with Tourette syndrome: Results from a randomized, double-blind, placebo-controlled phase 2b study. Presented at: American Academy of Neurology annual meeting; April 2-7, 2022; Seattle.

Vasileiou E, et al. Vitamin D polygenic score and multiple sclerosis outcomes. Presented at: ACTRIMS Forum; Feb. 24-26; West Palm Beach, Florida.

Cassidy J, et al. Impact of zolpidem in the treatment of prolonged disorders of consciousness. Presented at: American Academy of Neurology annual meeting; April 2-7, 2022; Seattle.

Shen MD, et al. Am J Psychiatry. 2022;doi:10.1176/appi.ajp.21090896

Disclosures: Please see each study for relevant financial disclosures.

In this edition, digital imaging and AI advance investigation of systemic disease through the retina; handheld retinal imaging devices may have utility in screening; Xipere launches in the US; and more.

Read the full coverage here:

Digital imaging, AI advance investigation of systemic disease through the retina

No additional visual benefit seen with nesvacumab-aflibercept combination in DME

Soft drusen, subretinal drusenoid deposits may be separate diseases leading to AMD

Xipere launches in US

Handheld retinal imaging devices may have utility in screening

References:

Healio Interviews

Brown DM, et al. Retina. 2022;doi:10.1097/IAE.0000000000003441.

Thomson RJ, et al. Retina. 2022;doi:10.1097/IAE.0000000000003460.

Press Release

Salongcay RP, et al. Ophthalmol Retina. 2022;doi:10.1016/j.oret.2022.03.002

In this edition, a phase 3 trial of a regimen for small cell lung cancer misses its co-primary endpoint; obesity and pulmonary function may identify the need for home oxygen after lung cancer surgery; a study finds that lung cancer screening is less common among those most likely to benefit from it; and more.

Read the full coverage here:

Phase 3 trial of regimen for small cell lung cancer misses co-primary endpoint

Obesity, pulmonary function may identify need for home oxygen after lung cancer surgery

Lung cancer screening less common among those most likely to benefit from it

FDA rejects sintilimab with chemotherapy for non-small cell lung cancer

Blood-based microRNA signature may predict survival in immunotherapy-treated NSCLC

References:

Press Release

Nicastri DG, et al. Ann Am Thorac Soc. 2022;doi:10.1513/AnnalsATS.202103-231OC.

Rustagi AS, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2022.5318.

Press Release

Rajakumar T, et al. npj Precis Oncol. 2022;doi:10.1038/s41698-022-00262-y.

This week, a speaker predicts the AMD epidemic will continue to challenge ophthalmologists; pegcetacoplan results in 18-month reduction in GA lesion growth; interim trial results show efficacy of photo-bio-modulation in dry AMD; and more.

Read the full coverage here:

AMD epidemic will continue to challenge ophthalmologists

Reduction in GA lesion growth continues at 18 months with pegcetacoplan

Interim trial results show efficacy of photobiomodulation in dry AMD

Ophthalmological manifestations observed in one-third of COVID-19 cases at single center

PDT may be effective for choroidal metastasis treatment

References:

Chew EY. Irving H. Leopold Lecture: Age-related macular degeneration: What have we learned from the age-related eye disease study (AREDS) and AREDS2? Presented at: Wills Eye Conference; March 10-12, 2022; Philadelphia.

Press Release

Press Release

Romero-Castro RM, et al. Retina. 2022;doi:10.1097/IAE.0000000000003457.

Sacconi R, et al. Retina. 2022;doi:10.1097/IAE.0000000000003305.

In this week's addition, the FDA approval of a transdermal patch to treat Alzheimer’s-related dementia; the link between daily napping among older adults and an increased risk for Alzheimer’s disease; an oral treatment for Parkinson’s demonstrated positive phase 2 results; and more.

Read the full coverage here:

FDA approves transdermal patch to treat Alzheimer’s-related dementia

Daily napping among older adults linked to a 40% higher risk for Alzheimer’s disease

Oral treatment for Parkinson’s shows positive phase 2 results

Sleep academy warns lawmakers about health risks of permanent daylight saving time

AAN: Medication, exercise more beneficial than stent in preventing stroke

References:

Press Release

Li P, et al. Alzheimers Dement. 2022;doi:10.1002/alz.12636.

Press Release

Press Release

Turan TN, et al. Neurology. 2022;doi:10.1212/WNL.0000000000200030.

In this edition, difficult-to-treat psoriatic arthritis 'not all about the therapies', Samsung biosimilar comparable to etanercept and more.

Read the full coverage here:

Difficult-to-treat psoriatic arthritis 'not all about the therapies'

Samsung biosimilar comparable to etanercept for psoriatic arthritis outcomes at 1 year

Boehringer Ingelheim, Quallent partner to expand Humira biosimilar access

VIDEO: Mitigating risk for psoriatic arthritis in patients with psoriasis

FDA approves high-concentration, citrate-free form of interchangeable biosimilar Cyltezo

References:

Healio Interview

Łosińska K, et al. Arthritis Care Res. 2024;doi:10.1002/acr.25345.

Ogdie-Beatty A. Psoriatic Arthritis in 2024. Presented at The Congress of Clinical Rheumatology East; May 9-12, 2024; Destin, Florida (hybrid meeting).

Press Release

Press Release

In this edition, smoking cessation support uptake at lung cancer screenings, glecirasib may deliver ‘efficacy and tolerability advantages’ and more.

Read the full coverage here:

Uptake of smoking cessation support high when offered at lung cancer screening

Glecirasib may deliver ‘efficacy and tolerability advantages’ for KRAS-mutant lung cancer

‘Substantial geographic disparities’ worsening in cancer clinical trial availability

Deployed military personnel have increased silica in lung tissue

FDA approves Alecensa for certain patients with ALK-positive lung cancer

References:

Lowers H, et al. Int J Environ Res Public Health. 2024;doi:10.3390/ijerph21010091.Press Release

Murray RL, et al. Eur Respir J. 2024;doi:10.1183/13993003.01768-2023.

Press Release

Sekar RR, et al. JAMA Netw Open. 2024;doi:10.1001/jamanetworkopen.2024.10162.

Shi Y, et al. Abstract 468214. Presented at: ASCO Plenary Series; April 30, 2024.

In this edition, FDA accepts new drug application for Eluminex, most mentors in vitreoretinal subspecialty are men and more.

Read the full coverage here:

FDA accepts investigational new drug application for Eluminex DME treatment

Most mentors in vitreoretinal subspecialty are men

Carotid artery stenosis linked to retinal changes in patients with diabetic retinopathy

AI-assisted technology makes retinal imaging 100 times faster, with greater contrast

FDA clears fully autonomous AI for portable diabetic retinopathy screening

References:

Das V, et al. Commun Med. 2024;doi:10.1038/s43856-024-00483-1.

Lee CY, et al. BMC Ophthalmol. 2024;doi:10.1186/s12886-024-03391-z.

Press Release

Press Release

Shah SM, et al. Demographics and productivity trends among academically affiliated female vitreoretinal specialists in the United States. Presented at: Real World Ophthalmology; April 27, 2024 (virtual meeting).

In this edition, FDA approves Selarsdi as Stelara biosimilar, deucravacitinib improves ‘broad range’ of patient-reported outcomes and more.

Read the full coverage here:

FDA approves Selarsdi as Stelara biosimilar for psoriasis, psoriatic arthritis

Deucravacitinib improves ‘broad range’ of patient-reported psoriatic arthritis outcomes

Advanced therapy not enough for nearly 75% of Canadian patients with psoriatic arthritis

New EULAR recommendations for psoriatic arthritis urge biologics after methotrexate failure

Dactylitis, enthesitis resolution linked to less pain, fatigue in guselkumab-treated PsA

References:

Gladman DD, et al. J Rheumatol. 2024;doi:10.3899/jrheum.2023-0716.

Gossec L, et al. Ann Rheum Dis. 2024;doi:10.1136/ard-2024-225531.

Press Release

Rahman P, et al. Clin Rheumatol. 2024;doi:10.1007/s10067-024-06921-8.

Strand V, et al. Arthritis Care Res. 2024;doi:10.1002/acr.25333.

In this edition, durvalumab improves survival in limited-stage small cell lung cancer, most adults do not test homes for radon exposure and more.

Read the full coverage here:

Durvalumab improves survival in limited-stage small cell lung cancer

Survey: Most adults do not test homes for radon exposure, unconcerned about risks

FDA fast tracks investigational bispecific therapy for aggressive lung cancer

Research shows complexity of shared decision-making about lung cancer screening

Keytruda-Lynparza combination misses survival targets in phase 3 lung cancer trial

References:

Núñez E, et al. Ann Fam Med. 2024;doi:10.1370/afm.3081.

Press Release

Press Release.

Press Release

Press Release

In this edition, PALADIN study navigates IOP-lowering surgery in DME patients, small-molecule eye drop well-tolerated as treatment for retinal vascular diseases and more.

Read the full coverage here:

PALADIN study: Navigating IOP-lowering surgery in DME patients for optimal outcomes

Small-molecule eye drop safe, well-tolerated as treatment for retinal vascular diseases

VIDEO: Reduction of vascular leakage, hyperreflective foci greater with faricimab

VIDEO: Real-world study shows durability of fluocinolone acetonide implant in DME

Early safety, efficacy results positive for Restoret in DME, wet AMD

References:

Chin Yee DS, et al. Outcomes in eyes requiring IOP-lowering surgery after treatment with the 0.19-mg fluocinolone acetonide implant for DME: The PALADIN study. Presented at: American Academy of Ophthalmology meeting; Nov. 3-6, 2023; San Francisco.

Graff JM. Biomarkers for vascular stability and inflammation demonstrate the benefit of dual Ang-2/VEGF-A inhibition with faricimab phase 3 trials in DME. Presented at: Retina 2024; Jan. 13-19, 2024; Wailea, Hawaii.

Minaker S. The 0.19mg fluocinolone acetonide (FAc) implant reduces the recurrence of edema by providing long-term control of retinal thickness variability in patients with DME: The 3-year PALADIN study. Presented at: Retina 2024; Jan. 13-19, 2024; Wailea, Hawaii.

Press Release

Press Release

In this edition, race identified as risk factor for VTE, FDA approves Rybrevant for treatment of non-small cell lung cancer and more.

Read the full coverage here:

Race identified as risk factor for VTE after pulmonary resection for lung cancer

FDA approves Rybrevant for treatment of non-small cell lung cancer

Behavioral health disorders have a ‘big impact’ on cancer surgery outcomes

Optimizing immunotherapy, biomarker testing vital to progress in lung cancer treatment

FDA approves Tagrisso plus chemotherapy for EGFR-mutated non-small cell lung cancer

References:

Axtell AL, et al. Ann Thorac Surg. 2024;doi:10.1016/j.athoracsur.2024.01.005.

Katayama ES, et al. J Am Coll Surgeons. 2024;doi:10.1097/XCS.0000000000000954.

Press Release

Press Release

Press Release

In this edition, blood test for lung cancer patients who may benefit from further immunotherapy, invasive procedures following lung cancer screenings and more.

Read the full coverage here:

Blood test identifies those with lung cancer who may benefit from further immunotherapy

Invasive procedures rarely follow false-positive lung cancer screenings

Study: Positive associations found between smoking and risk of ALS

Major cancer surgery associated with ‘elevated’ risk for venous thromboembolism

Quality improvement project bridges ‘significant gap’ in biomarker testing for lung cancer

References:

Anagnostou A, et al. Nat Med. 2023;doi:10.1038/s41591-023-02598-9.

Björklund J, et al. JAMA Netw Open. 2024;doi:10.1001/jamanetworkopen.2023.54352.

Healio Interviews

Kim YH, et al. Tob Induc Dis. 2024;doi:10.18332/tid/17531.

Manyak A, et al. CHEST. 2023;doi:10.1016/j.chest.2023.02.010.

In this edition, enrollment and dosing complete in phase 1 trial of AIV007, popular benchmarks in clinical practice guidelines and more.

Read the full coverage here:

Enrollment, dosing complete in phase 1 trial of AIV007 for AMD, diabetic macular edema

OCT, visual acuity popular benchmarks in clinical practice guidelines for DME

First patient dosed in phase 2 trial of EC-104 implant for diabetic macular edema

OCS-01 eye drop for DME in second stage of phase 3 trial

Q&A: Susvimo delivers immediate durability after implantation in wet AMD

References:

Crawford C. Update on OCS-01: A novel topical drop for DME in phase 3 trials. Presented at: Clinical Trials at the Summit; June 8, 2024; Park City, Utah.

Healio Interviews

McAllister M, et al. Assessing the strength of clinical practice guidelines for managing diabetic macular edema — A systematic literature review. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.

Press Release

Press Release

In this edition, FDA places hold on cell therapy trial after patient death, selpercatinib delivers superior outcomes and more.

Read the full coverage here:

FDA places hold on trial of cell therapy for lung cancer after patient death

Selpercatinib delivers superior outcomes, may ‘reduce the burden of NSCLC’

First-line immunotherapy benefits patients of all races with NSCLC equally

Never-smoker lung cancer survivors require targeted surveillance

Cemiplimab plus chemotherapy improves outcomes in metastatic NSCLC

References:

Baramidze A, et al. Abstract 1495P. Presented at: European Society for Medical Oncology Congress; Oct. 20-24, 2023; Madrid.

Choi E, et al. JAMA Netw. Open. 2023;doi:10.1001/jamanetworkopen.2023.43278.

Lee M, et al. J. Natl Compr Canc Netw. 2023;doi:10.6004/jnccn.2023.7064

Press Release

Zhou C, et al. N Engl J Med. 2023;doi:10.1056.NEJMoa2309457.

In this edition, an advocacy group petitions the FDA for stronger safety warnings for Botox, melanoma regression is associated with improved prognosis and more.

Read the full coverage here:

Advocacy group petitions FDA for stronger safety warnings for Botox, related drugs

Melanoma regression associated with improved prognosis

Phase 4 results show Vtama cream efficacious in head, neck plaque psoriasis

Isotretinoin not associated with increased risk for suicide, psychiatric conditions

Tape strips may identify hidradenitis suppurativa in lesional, nonlesional skin

References:

Navrazhina K, et al. J Am Acad Dermatol. 2023;doi:10.1016/j.jaad.2023.11.048.

Press Release

Press Release

Tan NKW, et al. JAMA Dermatol. 2023;doi:10.1001/jamadermatol.2023.4579.

Wagner NB, et al. J Am Acad Dermatol. 2023;doi:10.1016/j.jaad.2023.11.040.

In this edition, allergic illnesses in children may be inherited from mothers; addressing needs of Muslim patients in dermatology; YouTube content on topical steroid withdrawal exhibits poor reliability and more.

Read the full coverage here:

Atopic dermatitis, other allergic illnesses in children may be inherited from mothers

Addressing needs of Muslim patients in dermatology

YouTube content on topical steroid withdrawal exhibits poor reliability, quality

RelabotulinumtoxinA demonstrates rapid onset, durability for frown lines, crow’s feet

Puberty, skin of color, weight associated with acne prevalence among adolescents

References:

Chiesa Fuxench ZC, et al. J Am Acad Dermatol. 2023;doi:10.1016/j.jaad.2023.11.013.

El-Banna G, et al. JAMA Dermatol. 2023;doi:10.1001/jamadermatol.2023.4439.

McCormick E, et al. J Drugs Dermatol. 2023;doi:10.36849/JDD.C7443.

Press Release

Witkam WCAM, et al. J Am Acad Dermatol. 2023;doi:10.1016/j.jaad.2023.10.062.

In this edition, dermatologists ‘uniquely positioned’ to aid human trafficking victims; FDA approves Cosentyx for hidradenitis suppurativa and more.

Read the full coverage here:

Dermatologists ‘uniquely positioned’ to recognize, aid human trafficking victims

FDA approves Cosentyx as first IL-17A inhibitor for hidradenitis suppurativa

FDA approves Stelara biosimilar for treatment of psoriasis, multiple inflammatory diseases

RECELL system efficacious in vitiligo repigmentation

Isotretinoin efficacious in seborrheic dermatitis treatment

References:

Elbuluk N. Optimizing melanocyte cell transplant procedure for treatment of vitiligo. Presented at: American Society for Dermatologic Surgery Annual Meeting; Nov 1-5, 2023; Chicago.

Kourosh S. The role of dermatologic surgeons in advocating for those affected by human trafficking. Presented at: American Society for Dermatologic Surgery Annual Meeting; Nov 1-5, 2023; Chicago.

Press Release

Press Release

Tan MG, et al. Isotretinoin for the management of moderate to severe seborrheic dermatitis. Presented at: American Society for Dermatologic Surgery Annual Meeting; Nov 1-5, 2023; Chicago.

In this edition, multicancer detection tests show promise; lifestyle counseling appointments benefit cancer survivors; use of low-value drugs for patients with cancer, and more.

Read the full coverage here:

Multicancer detection tests show promise, but questions linger about their accessibility

Shared medical appointments for lifestyle counseling benefit cancer survivors

Industry payments to physicians spur use of low-value drugs for patients with cancer

Study shows link between ultraprocessed foods and mortality risk

Radiation oncologist appointed to leadership role at NYU Langone’s Perlmutter Cancer Center

References:

Mitchell AP, et al. BMJ. 2023;doi:10.1136/bmj-2023-075512.

Press Release

Westgate C, Fischer J. What primary care physicians need to know about multicancer early detection tests. Presented at: OMED; Oct. 5-8, 2023.

Winters LN. The development of an advanced practice nurse and registered dietician-led lifestyle medicine shared medical appointment program for cancer survivors. Presented at: Lifestyle Medicine 2023; Denver; Oct. 29-Nov. 1, 2023.

Zhao Y, et al. Am J Prev Med. 2023;doi:10.1016/j.amepre.2023.09.005.

In this edition, FDA approves Bimzelx for plaque psoriasis; roflumilast foam improves quality of life in patients with seborrheic dermatitis and more.

Read the full coverage here:

FDA approves Bimzelx for treatment of moderate to severe plaque psoriasis

Roflumilast foam improves quality of life in patients with seborrheic dermatitis

Opzelura effective, well tolerated in children aged at least 2 years with atopic dermatitis

Treatment for onychomycosis prescribed at only 20% of visits, impacting quality of life

Study: Important to weigh berdazimer gel benefits vs. risks in molluscum contagiosum

References:

Calvi IP, et al. Pediatr Dermatol. 2023;doi:10.1111/pde.15419.

Chu D. et al. Poster. Effect of roflumilast foam 0.3% on quality of life in patients with seborrheic dermatitis: patient-reported outcomes from the STRATUM phase III trial. Presented at: AMCP Nexus; Orlando.

Peck GM, et al. J Drugs Dermatol. 2023;doi:10.36849/JDD.6770.

Press Release

Press Release

In this edition, FDA issues complete response letter for relabotulinumtoxinA; mucocutaneous manifestations may signal COVID-induced inflammatory disease in children and more.

Read the full coverage here:

FDA issues complete response letter for relabotulinumtoxinA for frown lines, crow’s feet

Mucocutaneous manifestations may signal COVID-induced inflammatory disease in children

FDA approves Zoryve for pediatric psoriasis

Colloidal oatmeal, prescription cream comparable in Black children with atopic dermatitis

FDA issues complete response letter for lebrikizumab for eczema treatment

References:

Imam B. Mucocutaneous clinical manifestation of multi-system inflammatory syndrome in children (MIS-C). Presented at: Skin of Color Update; Oct. 6-8, 2023; New York.

Lisante TA, et al. J Dermatolog Treat. 2023;doi:10.1080/09546634.2023.2241587.

Press Release

Press Release

Press Release

In this edition, precision navigators reduce racial disparities in genomic testing; cancer diagnoses fell sharply during early days of pandemic; Prostate Cancer Awareness Month updates, and more.

Read the full coverage here:

Precision navigators reduce racial disparities in genomic testing for prostate cancer

Cancer diagnoses fell sharply during early days of pandemic, NCI report shows

Prostate Cancer Awareness Month: Financial hardship common, exercise beneficial

Researchers identify 11 genes linked to aggressive prostate cancer

Black men less likely to receive targeted therapy for metastatic prostate cancer

References:

Allen AJ, et al. Abstract 122. Presented at: ASTRO Annual Meeting; Oct. 1-4, 2023; San Diego.

Darst BF, et al. JAMA Oncol. 2023;doi:10.1001/jamaoncol.2023.3482.

Healio Coverage

Hwang C, et al. JAMA Netw Open. 2023;doi:10.1001/jamanetworkopen.2023.34208.

Negoita S, et al. Cancer. 2023;doi:10.1002/cncr.35026.

In this edition, retinoids and OTC products for photoaged skin; fractional lasers show promise in skin cancer prevention; a botanical drug for severe thermal burns and more.

Read the full coverage here:

Prescription retinoids, OTC products positively impact photoaged skin

Fractional lasers show promise in skin cancer prevention

Botanical drug may outperform standard of care for treatment of severe thermal burns

5-fluorouracil cream noninferior to surgery for Bowen’s disease

Perifollicular linear projections aid in early diagnosis of facial lentigo maligna

References:

Ahmady S, et al. J Am Acad Dermatol. 2023;doi:10.1016/j.jaad.2023.08.076.

McCormick ET, et al. J Drugs Dermatol. 2023;doi:10.36849/JDD.2023.NVRN0923.

Navarrete-Dechent C, et al. J Am Acad Dermatol. 2023;doi:10.1016/j.jaad.2023.07.1036.

Press Release

Sadick N, et al. J Drugs Dermatol. 2023;doi:10.36849/JDD.7753.

In this edition, CDC issues a health advisory concerning flesh-eating bacterium, staging for melanoma does not represent accurate recurrence and mortality and more.

Read the full coverage here:

CDC issues health advisory about recent reports of fatal Vibrio vulnificus

Study finds melanoma treatment costs have increased, but so has survival

Melanoma staging system inaccurately reflects recurrence, mortality risk

Study: Nemolizumab shows promise as prurigo nodularis treatment

Adverse events after ICI treatment linked to improved outcomes in patients with melanoma

References:

Bateni SB, et al. JAMA Dermatol. 2023;doi:10.1001/jamadermatol.2023.3179.

Deng J, et al. JAMA Dermatol. 2023;doi:10.1001/jamadermatol.2023.2609.

Du Y, et al. JAMA Dermatol. 2023;doi:10.1001/jamadermatol.2023.3003.

Helvind NM, et al. JAMA Dermatol. 2023;doi:10.1001/jamadermatol.2023.3256.

Press Release

In this edition, drug discounts through Medicare price negotiations, opioid use has fallen 15% annually since 2014 and more.

Read the full coverage here:

Enbrel, Stelara to be discounted nearly 70% through Medicare price negotiations

Opioid use has fallen 15% annually since 2014 in autoimmune rheumatic disease

Inhibitor class PsO treatments exhibit similar efficacy in mitigating PsA risk

S100 protein levels predict abatacept response in juvenile idiopathic arthritis

Izokibep shows early promise in hidradenitis suppurativa

References:

Brunner HI, et al. Arthritis Res Ther. 2024;doi:10.1186/s13075-024-03347-0.

Falasinnu T, et al. Lancet Rheumatol. 2024;doi:10.1016/S2665-9913(24)00120-6.

Press Release

Press Release

Tsai SHL, et al. J Am Acad Dermatol. 2024;doi:10.1016/j.jaad.2024.07.1473.

In this edition, nearly $1 million in grants to aid diversity, equity, inclusion research; topical halcinonide may benefit patients with psoriasis; Asian patients may experience earlier mycosis fungoides diagnosis and more.

Read the full coverage here:

Nearly $1 million in grants to aid dermatology research in diversity, equity, inclusion

Topical halcinonide may benefit patients with psoriasis with inadequate biologics response

Asian patients may experience earlier mycosis fungoides diagnosis, better outcomes

COVID-19 pandemic led to delayed melanoma diagnoses, more advanced tumors

Dupilumab use correlates with S. aureus reductions, atopic dermatitis improvements

References:

Bagel J, et al. J Drugs Dermatol. 2023;doi:10.36849/JDD.6830.

Chen Z, et al. JAMA Dermatol. 2023;doi:10.1001/jamadermatol.2023.2634.

Press Release

Simpson EL, et al. J Allergy Clin Immunol. 2023;doi:10.1016/j.jaci.2023.05.026.

Xiong D, et al. J Am Acad Dermatol. 2023;doi:10.1016/j.jaad.2023.08.040.

In this edition, ‘equitable access’ to care may reduce racial disparities in survival; exercise may improve sexual function among men with prostate cancer; image-guided adaptive prostate radiation therapy for short-term toxicities, and more.

Read the full coverage here:

‘Equitable access’ to care may reduce racial disparities in prostate cancer survival

Exercise may improve sexual function among men with prostate cancer

Image-guided adaptive prostate radiation therapy reduces risk for short-term toxicities

Recent developments in advanced prostate cancer space pave way for future breakthroughs

Radiation plus intensive systemic therapy improves outcomes in prostate cancer subset

References:

Bossi A, et al. Abstract LBA5000. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago.

Galvao DA, et al. Abstract 71. Presented at: ASCO Breakthrough; Aug. 3-5, 2023; Yokohama.

Leeman JE, et al. Cancer.2023;doi:10.1002/cncr.34836.

Sayegh N, et al. JAMA Netw Open. 2023;doi:10.1001/jamanetworkopen.2023.26546.

Sharifi N, et al. J Clin Oncol. 2023;doi:10.1200/JCO.2022.40.16_suppl.5022.

In this edition, M-PDT efficacy similar to isotretinoin in acne vulgaris; Spitz neoplasm diagnosis in adults; immunotherapy treatment shows promise in basal cell carcinoma and more.

Read the full coverage here:

M-PDT efficacy similar to isotretinoin in acne vulgaris

Clinicians should not ‘shy away’ from a Spitz neoplasm diagnosis in adults

Novel nonsurgical immunotherapy treatment shows promise in basal cell carcinoma

Remibrutinib potential first-in-class oral treatment for chronic spontaneous urticaria

Clascoterone cream exhibits significant long-term improvement among children with acne

References:

Eichenfield LF, et al. J Drugs Dermatol. 2023;doi:10.36849/JDD.7592.

Hagstrom M, et al. J Am Acad Dermatol. 2023;doi:10.1016/j.jaad.2023.08.005.

Press Release

Press Release

Zhang L, et al. J Am Acad Dermatol. 2023;doi:10.1016/j.jaad.2023.07.1023.

In this edition, nonalcoholic muscadine wine may improve aging skin; atopic disease risk increases in sexually diverse patients; AI doubles diagnostic accuracy among patients with skin of color and more.

Read the full coverage here:

Nonalcoholic muscadine wine may improve aging skin in older women

Atopic disease risk increases in sexually diverse patients

AI doubles diagnostic accuracy of skin conditions among patients with skin of color

Post-acne scarring should be treated as primary skin condition

Histologic margin status can help predict lentigo maligna melanoma recurrence

References:

Christman L. Dealcoholized muscadine wine improved skin health, reduced oxidative stress and inflammation in women in a randomized controlled trial. Presented at: NUTRITION; July 22-25, 2023; Boston.

Hoang MP, et al. J Am Acad Dermatol. 2023;doi:10.1016/j.jaad.2023.07.008.

Rypka KJ, A, et al. JAMA Dermatol. 2023;doi:10.1001/jamadermatol.2023.1934.

Schneider JG, et al. J Drugs Dermatol. 2023;doi:10.36849/JDD.7581.

Zhou C, et al. Clin Cosmet Investig Dermatol. 2023;doi:10.2147/CCID.S406235.

In this edition, FDA approves Vanflyta for newly diagnosed AML; liso-cel could have ‘best shot’ at remission for double refractory CLL; mortality factors among cancer survivors and more.

Read the full coverage here:

FDA approves Vanflyta for newly diagnosed acute myeloid leukemia

VIDEO: Liso-cel could have ‘best shot’ at remission for double refractory CLL

Community affluence, insurance mediate CV mortality among Black, white cancer survivors

VIDEO: MOLTO study probes combination therapy in Richter syndrome

Gilead terminates phase 3 trial of magrolimab regimen for myelodysplastic syndrome

References:

ASCO Annual Meeting

ASCO Annual Meeting

Press Release

Press Release

Sung H, et al. Int J Epidemiol. 2023;doi:10.1093/ije/dyad097.

In this edition, lack of sunless tanner education may cause confusion; intralesional HPV vaccine may clear recalcitrant warts; Ilumetri improves well-being of patients with plaque psoriasis and more.

Read the full coverage here:

Lack of sunless tanner education may cause diagnostic confusion, UV exposure

Intralesional HPV vaccine may clear recalcitrant warts

New, positive results show Ilumetri improves well-being of patients with plaque psoriasis

AB-101a rapidly reduces itch in patients aged as young as 2 years with atopic dermatitis

TikTok ‘excellent opportunity’ for dermatologists to create skin of color content

References:

Campbell JR, et al. J Drugs Dermatol. 2023;doi:10.36849/JDD.7061.

Hatch J, et al. Poster. Sunless tanners: An analysis of most common ingredients. Presented at: American Academy of Dermatology Annual Meeting; March 17-21, 2023; New Orleans.

Nofal A, et al. J Am Acad Dermatol. 2023;doi:10.1016/j.jaad.2023.06.042.

Press Release

Spelman L, et al. Phase 2 trial of novel topical drug candidate AB-101a for treatment of mild to moderate atopic dermatitis in children and adults. Presented at: 25th World Congress of Dermatology; July 3-8, 2023; Singapore.

In this edition, obesity linked to adverse outcomes among AYAs; pirtobrutinib produces high response rates; CDC study reveals overall increase in pediatric cancer incidence and more.

Read the full coverage here:

Overweight, obesity linked to adverse outcomes among AYAs treated for leukemia

Pirtobrutinib produces high response rates in heavily pretreated CLL, SLL

CDC study reveals overall increase in pediatric cancer incidence over 16 years

Cancers with high incidence among racial/ethnic minorities receive less research funding

Women more likely to experience severe toxicity from cancer treatment

References:

Haghighat S, et al. J Natl Cancer Inst. 2023;doi:10.1093/jnci/djad097.

Mato AR, et al. N Engl J Med. 2023;doi:10.1056/NEJMoa2300696.

Shimony S, et al. Blood Adv. 2023;doi:10.1182/bloodadvances.2023009976.

Siegel DA, et al. J Natl Cancer Inst. 2023;doi:10.1093/jnci/djad115.

Unger JM, et al. Abstract SY43-03. Presented at American Association for Cancer Research Annual Meeting; April 14-19, 2023; Orlando.

In this edition, novel serum improves hair growth in androgenetic alopecia; cardiovascular disease linked to dermatological inflammatory diseases; sugary drinks may be associated with male pattern hair loss and more.

Read the full coverage here:

Novel serum improves hair growth in androgenetic alopecia with no side effects

Cardiovascular disease associated with four dermatological inflammatory diseases

Consumption of sugary drinks may be associated with male pattern hair loss

Researchers advocate for promotion of skin self-examination for early melanoma detection

Plaque psoriasis oral therapy moves to phase 3 trial, being tested in other conditions

References:

Ingrassia JP, et al. J Am Acad Dermatol. 2023;doi:10.1016/j.jaad.2023.05.098.

Pagan AD, et al. J Drugs Dermatol. 2023;doi:10.36849/JDD.7424.

Press Release

Rapaport J, et al. J Drugs Dermatol. 2023;doi:10.36849/JDD.7403.

Shi X, et al. Nutrients. 2023;doi:10.3390/nu15010214.

In this edition, CAR-T trial for leukemia paused after patient death; obesity may increase risk for blood cancer; new CAR T-cell therapies ‘waiting’ for patients with leukemia and more.

Read the full coverage here:

Seattle Children’s pauses trial of CAR-T for leukemia after patient death

Obesity may increase risk for blood cancer

VIDEO: New CAR T-cell therapies ‘waiting in the wings’ for patients with leukemia

VIDEO: Jaktinib shows promise in treatment of myelofibrosis

Venetoclax regimen not superior to standard therapy alone for older patients with CLL

References:

ASCO Annual Meeting

ASCO Annual Meeting

Pasupuleti SK, et al. J Clin Invest. 2023;doi:10.1172/JCI163968.

Press Release

Woyach JA, et al. Abstract 7500. Presented at: ASCO Annual Meeting 2023; June 2-6, 2023; Chicago.